Vivoryon Therapeutics N.V. announced the appointment of Anne Doering as Chief Financial Officer (CFO), leveraging Ms. Doering?s deep capital markets experience and enabling a smooth management transition as she succeeds Florian Schmid on March 1, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.845 EUR | +9.74% | +30.40% | -89.62% |
24/04 | Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024 | |
15/03 | Vivoryon Therapeutics N.V Announces Resignation of Board of Directors | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-89.62% | 23.74M | |
+21.74% | 46.4B | |
-0.97% | 41.75B | |
+47.07% | 41.37B | |
-3.52% | 29.71B | |
+11.12% | 26.01B | |
-19.37% | 19.52B | |
+31.18% | 12.43B | |
-0.04% | 12.13B | |
+0.39% | 12.18B |
- Stock Market
- Equities
- VVY Stock
- News Vivoryon Therapeutics N.V.
- Vivoryon Therapeutics N.V. Announces Executive Changes